Drug intelligence / Profile preview

HN-2301

Development stage: Phase 1
Lead developer: MagicRNA Biotechnology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Injection

Overview

HN-2301 is an investigational mRNA-based therapy delivered via modified lipid nanoparticles, currently in clinical development for the treatment of systemic lupus erythematosus (SLE). The drug functions as a CD19 modulator, targeting B lymphocyte antigen CD19 to modulate immune responses implicated in autoimmune diseases. It is being developed by Shenzhen Hongxin Biotechnology and Shenzhen MagicRNA Biotechnology. Clinical trials are ongoing to assess its safety and efficacy in patients with relapsing and refractory SLE[1][2][3][5].

Other names: HN2301 injectionHN-2301 injectionHN 2301 injection

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on HN-2301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HN-2301.

Explore the full profile